Galapagos sources CEO for oncology spin-off as Stoffels plans exit
Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a major step in the company’s planned division into two focused businesses.
The new subsidiary, currently named SpinCo, will be launched with around 2.45 billion euros ($2.61 billion) in funding. It will focus on acquiring or advancing drug candidates with clinical proof-of-concept and potential to raise the standard of care in serious diseases.
Mr Gosebruch, a seasoned biotech dealmaker, most recently led Neumora (Nasdaq: NMRA) through its initial public offering in 2023. Prior to that, he was chief strategy officer at AbbVie (NYSE: ABBV), where he helped drive the $63 billion Allergan acquisition and oversaw deals for key assets such as psoriasis treatment Skyrizi (risankizumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze